- Home
- MATV vs JANX Comparison
MATV vs JANX Comparison
Compare MATV & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MATV | JANX |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 701.0M | 790.3M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MATV | JANX |
|---|---|---|
| Price | $10.74 | $13.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $10.00 | ★ $52.45 |
| AVG Volume (30 Days) | 344.4K | ★ 1.0M |
| Earning Date | 05-21-2026 | 06-01-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $4.63 | N/A |
| Revenue Next Year | $3.37 | $235.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.34 | $12.12 |
| 52 Week High | $15.48 | $35.34 |
Technical Indicators
Market Signals| Indicator | MATV | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 32.10 | 45.87 |
| Support Level | $9.95 | $13.03 |
| Resistance Level | $11.54 | $13.79 |
| Average True Range (ATR) | 0.75 | 0.50 |
| MACD | -0.39 | 0.14 |
| Stochastic Oscillator | 4.60 | 55.56 |
Price Performance
Historical ComparisonAbout MATV Mativ Holdings Inc.
Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments namely Filtration & advanced Materials focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging and healthcare solutions.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.